EZH2 and neoplasm: Those mutations lead to an upregulation of the enhancer of zeste homolog 2 (EZH2) activity, a subunit of Polycomb repressive complex 2 (PRC2), known as a tumor driver and thus a potential therapeutic target in chordomas [27].